A study shows that a formulation of curcumin can relieve pain and increase mobility in patients with osteoarthritis. It can also reduce a series of inflammatory markers.
100 patients with osteoarthritis were divided in two groups -- the first group was given the "best available treatment" and the second group was given the same treatment plus 200 mg of the curcumin formulation each day.
According to IFT:
"The results showed that the [curcumin]-treated group had a statistically significant reduction in all primary clinical end-points ... These results were complemented by the evaluation of a series of inflammatory markers, soluble vascular cell adhesion molecule (sVCAM)-1, and erythrocyte sedimentation rate [ESR]) ... while no significant variation was observed in the 'best available treatment' group."
This could eventually lead to a phase out of NSAID use, at least as a treatment for mild-to-moderate osteoarthritis.